<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026074</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT04026074</nct_id>
  </id_info>
  <brief_title>Concepts for Analgosedation During Placement of Regional Anaesthesia Before Operations.</brief_title>
  <official_title>Randomized Controlled Doubleblind Pilot Study Comparing Analgosedation Concepts During Placement of Regional Anaesthesia With Either Fentanyl, Remifentanil, Clonidine, EMLA-Patch or Placebo in Regard of Pain Reduction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to specify the best analgosedation technique during placement of regional
      anaesthesia from the patients' view.

      In this double blind randomized trial the investigators will be testing the application of
      drugs administered intravenously (fentanyl-bolus, remifentanil-infusion, clonidine-bolus) or
      transcutaneously (EMLA salve) or placebo (NaCl 0,9% i.v. and skin protection salve).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this doubleblind randomized pilot trial, patients will receive one of five possible
      combinations to assess which medication leads to the best medication during placement of
      regional anaesthesia. This assessement includes NRS, patients' satisfaction and wellbeing.
      The tested substances will be administered intravenously (fentanyl-bolus,
      remifentanil-infusion, clonidine-bolus) or transcutaneously (EMLA salve). The fifth
      combination will be the control group with only placebo medication. We expected to get first
      information for objectifying analgosedation during placement of regional anaesthesia for the
      conduction of further studies in this field.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 26, 2019</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity during placement of the regional anaesthesia</measure>
    <time_frame>1 day</time_frame>
    <description>Pain assessment during placement of the regional anaesthesia with the Numeric Rating Scale (NRS 1 to 10, with 1=lowest pain score, 10=highest pain score). Lower NRS describes a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' wellbeing</measure>
    <time_frame>1 day</time_frame>
    <description>Wellbeing assessment during placement of the regional anaesthesia with the anaesthesiological questionnaire (ANP anaesthesiological Questionnaire is a self-rating method for the assessment of postoperative complaints, patient wellbeing and satisfaction. The rating scales from 0 to 3, with 0=&quot;none&quot; and 3=&quot;strongly&quot;). Higher wellbeing values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate (delirium, allergic reactions, cardiopulmonary decompensation)</measure>
    <time_frame>Through study completion, an average of 1 day</time_frame>
    <description>Complications on operation day will be recorded and compared between the treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Knee Arthropathy</condition>
  <condition>Hip Arthritis</condition>
  <condition>Fractures, Closed</condition>
  <arm_group>
    <arm_group_label>Fentanyl i.v. (intravenously)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered the medication and additionally will be treated with placebo salve (skin protection salve)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMLA salve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be administered the medication (salve) and additionally will be administered i.v. saline as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be administered i.v. placebo (0,9% NaCl) and placebo salve (skin protection salve)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Weight adapted drug application</description>
    <arm_group_label>Fentanyl i.v. (intravenously)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Weight adapted drug application</description>
    <arm_group_label>Remifentanil i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Weight adapted drug application</description>
    <arm_group_label>Clonidine i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMLA Cream</intervention_name>
    <description>Salve application on the body part where the regional anaesthesia will be administered</description>
    <arm_group_label>EMLA salve</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo iv</intervention_name>
    <description>i.v. administration of 0,9% NaCl</description>
    <arm_group_label>EMLA salve</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo salve</intervention_name>
    <description>Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered</description>
    <arm_group_label>Clonidine i.v.</arm_group_label>
    <arm_group_label>Fentanyl i.v. (intravenously)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Remifentanil i.v.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients planed electively for orthopedic surgery

        Exclusion Criteria:

          -  Missing patient's consent

          -  Intolerance against study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregor A Schittek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Hospital LKH Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Fractures, Closed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Lidocaine, Prilocaine Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publication of our results, all data will be made available in respect to the austrian data privacy laws</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After publication of our results, all data will be made available in respect to the austrian data privacy laws. Expected for Summer 2020.</ipd_time_frame>
    <ipd_access_criteria>Research groups interested in the data will be granted access.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

